Supplementary Material

Etiology-specific incidence and mortality of diarrheal diseases in the African region: a systematic review and meta-analysis
Thystrup et al.

Contents

Supplementary Search String 1: Search String for PubMed

"2021/04/30"[PDat]) AND (Humans[Mesh]) AND (Clinical Trial[ptyp] ORMeta-Analysis[ptyp] OR Randomized Controlled Trial[ptyp] OR Review[ptyp]OR Clinical Trial, Phase I[ptyp] OR Clinical Trial, Phase II[ptyp] OR Clini-cal Trial, Phase III[ptyp] OR Clinical Trial, Phase IV[ptyp] OR ComparativeStudy[ptyp] OR Controlled Clinical Trial[ptyp] OR Corrected and Repub-lished Article[ptyp] OR English Abstract[ptyp] OR Evaluation Studies[ptyp]OR Journal Article[ptyp] OR Multicenter Study[ptyp] OR Research Support,N I H, Extramural[ptyp] OR Research Support, N I H, Intramural[ptyp] ORResearch Support, Non U S Gov't[ptyp] OR Research Support, U S Gov't,Non P H S[ptyp] OR Research Support, U S Gov't, P H S[ptyp] OR TwinStudy[ptyp] OR Validation Studies[ptyp]) AND (child[MeSH:noexp] OR ado-lescent[MeSH] OR adult[MeSH:noexp] OR middle age[MeSH] OR (middleage[MeSH] OR aged[MeSH]) OR aged[MeSH] OR aged, 80 and over[MeSH])))NOT (((diarrhea AND morbidity AND (("2014/01/01"[PDat] : "2021/04/30"[PDat])AND (Humans[Mesh]) AND (Clinical Trial[ptyp] OR Meta-Analysis[ptyp]OR Randomized Controlled Trial[ptyp] OR Review[ptyp] OR Clinical Trial,Phase I[ptyp] OR Clinical Trial, Phase II[ptyp] OR Clinical Trial, Phase III[ptyp]OR Clinical Trial, Phase IV[ptyp] OR Comparative Study[ptyp] OR Con-trolled Clinical Trial[ptyp] OR Corrected and Republished Article[ptyp] OREnglish Abstract[ptyp] OR Evaluation Studies[ptyp] OR Journal Article[ptyp]OR Multicenter Study[ptyp] OR Research Support, N I H, Extramural[ptyp]OR Research Support, N I H, Intramural[ptyp] OR Research Support, NonU S Gov't[ptyp] OR Research Support, U S Gov't, Non P H S[ptyp] ORResearch Support, U S Gov't, P H S[ptyp] OR Twin Study[ptyp] OR Val-idation Studies[ptyp]) AND (child[MeSH:noexp] OR adolescent[MeSH] ORadult[MeSH:noexp] OR middle age[MeSH] OR (middle age[MeSH] OR aged[MeSH])OR aged[MeSH] OR aged, 80 and over[MeSH]))) OR (diarrhea AND mortal-ity AND (("2014/01/01"[PDat] : "2021/04/30"[PDat]) AND (Humans[Mesh])AND (Clinical Trial[ptyp] OR Meta-Analysis[ptyp] OR Randomized Con-trolled Trial[ptyp] OR Review[ptyp] OR Clinical Trial, Phase I[ptyp] OR Clin-ical Trial, Phase II[ptyp] OR Clinical Trial, Phase III[ptyp] OR Clinical Trial,Phase IV[ptyp] OR Comparative Study[ptyp] OR Controlled Clinical Trial[ptyp]OR Corrected and Republished Article[ptyp] OR English Abstract[ptyp] OREvaluation Studies[ptyp] OR Journal Article[ptyp] OR Multicenter Study[ptyp]OR Research Support, N I H, Extramural[ptyp] OR Research Support, NI H, Intramural[ptyp] OR Research Support, Non U S Gov't[ptyp] OR Re-search Support, U S Gov't, Non P H S[ptyp] OR Research Support, U SGov't, P H S[ptyp] OR Twin Study[ptyp] OR Validation Studies[ptyp]) AND (child[MeSH:noexp] OR adolescent[MeSH] OR adult[MeSH:noexp] OR mid-dle age[MeSH] OR (middle age[MeSH] OR aged[MeSH]) OR aged[MeSH]OR aged, 80 and over[MeSH]))) OR (diarrhea AND etiology AND (("2014/01/01"[PDat]: "2021/04/30"[PDat]) AND (Humans[Mesh]) AND (Clinical Trial[ptyp] ORMeta-Analysis[ptyp] OR Randomized Controlled Trial[ptyp] OR Review[ptyp]OR Clinical Trial, Phase I[ptyp] OR Clinical Trial, Phase II[ptyp] OR Clini-cal Trial, Phase III[ptyp] OR Clinical Trial, Phase IV[ptyp] OR ComparativeStudy[ptyp] OR Controlled Clinical Trial[ptyp] OR Corrected and Repub-lished Article[ptyp] OR English Abstract[ptyp] OR Evaluation Studies[ptyp]OR Journal Article[ptyp] OR Multicenter Study[ptyp] OR Research Support,N I H, Extramural[ptyp] OR Research Support, N I H, Intramural[ptyp] ORResearch Support, Non U S Gov't[ptyp] OR Research Support, U S Gov't,Non P H S[ptyp] OR Research Support, U S Gov't, P H S[ptyp] OR TwinStudy[ptyp] OR Validation Studies[ptyp]) AND (child[MeSH:noexp] OR ado-lescent[MeSH] OR adult[MeSH:noexp] OR middle age[MeSH] OR (middleage[MeSH] OR aged[MeSH]) OR aged[MeSH] OR aged, 80 and over[MeSH])))AND cancer)) NOT ((((diarrhea AND morbidity AND (("2014/01/01"[PDat]: "2021/04/30"[PDat]) AND

(Humans[Mesh]) AND (Clinical Trial[ptyp] ORMeta-Analysis[ptyp] OR Randomized Controlled Trial[ptyp] OR Review[ptyp]OR Clinical Trial, Phase I[ptyp] OR Clinical Trial, Phase II[ptyp] OR Clini-cal Trial, Phase III[ptyp] OR Clinical Trial, Phase IV[ptyp] OR ComparativeStudy[ptyp] OR Controlled Clinical Trial[ptyp] OR Corrected and Repub-lished Article[ptyp] OR English Abstract[ptyp] OR Evaluation Studies[ptyp]OR Journal Article[ptyp] OR Multicenter Study[ptyp] OR Research Support,N I H, Extramural[ptyp] OR Research Support, N I H, Intramural[ptyp] ORResearch Support, Non U S Gov't[ptyp] OR Research Support, U S Gov't,Non P H S[ptyp] OR Research Support, U S Gov't, P H S[ptyp] OR TwinStudy[ptyp] OR Validation Studies[ptyp]) AND (child[MeSH:noexp] OR ado-lescent[MeSH] OR adult[MeSH:noexp] OR middle age[MeSH] OR (middleage[MeSH] OR aged[MeSH]) OR aged[MeSH] OR aged, 80 and over[MeSH]))OR (diarrhea AND mortality AND (("2014/01/01"[PDat] : "2021/04/30"[PDat])AND (Humans[Mesh]) AND (Clinical Trial[ptyp] OR Meta-Analysis[ptyp]OR Randomized Controlled Trial[ptyp] OR Review[ptyp] OR Clinical Trial,Phase I[ptyp] OR Clinical Trial, Phase II[ptyp] OR Clinical Trial, Phase III[ptyp]OR Clinical Trial, Phase IV[ptyp] OR Comparative Study[ptyp] OR Con-trolled Clinical Trial[ptyp] OR Corrected and Republished Article[ptyp] OREnglish Abstract[ptyp] OR Evaluation Studies[ptyp] OR Journal Article[ptyp]OR Multicenter Study[ptyp] OR Research Support, N I H, Extramural[ptyp] Appendix A. Appendix A: Search strings65OR Research Support, N I H, Intramural[ptyp] OR Research Support, NonU S Gov't[ptyp] OR Research Support, U S Gov't, Non P H S[ptyp] ORResearch Support, U S Gov't, P H S[ptyp] OR Twin Study[ptyp] OR Val-idation Studies[ptyp]) AND (child[MeSH:noexp] OR adolescent[MeSH] ORadult[MeSH:noexp] OR middle age[MeSH] OR (middle age[MeSH] OR aged[MeSH])OR aged[MeSH] OR aged, 80 and over[MeSH])) OR (diarrhea AND etiologyAND (("2014/01/01"[PDat] : "2021/04/30"[PDat]) AND (Humans[Mesh])AND (Clinical Trial[ptyp] OR Meta-Analysis[ptyp] OR Randomized Con-trolled Trial[ptyp] OR Review[ptyp] OR Clinical Trial, Phase I[ptyp] OR Clin-ical Trial, Phase II[ptyp] OR Clinical Trial, Phase III[ptyp] OR Clinical Trial,Phase IV[ptyp] OR Comparative Study[ptyp] OR Controlled Clinical Trial[ptyp]OR Corrected and Republished Article[ptyp] OR English Abstract[ptyp] OREvaluation Studies[ptyp] OR Journal Article[ptyp] OR Multicenter Study[ptyp]OR Research Support, N I H, Extramural[ptyp] OR Research Support, NI H, Intramural[ptyp] OR Research Support, Non U S Gov't[ptyp] OR Re-search Support, U S Gov't, Non P H S[ptyp] OR Research Support, U SGov't, P H S[ptyp] OR Twin Study[ptyp] OR Validation Studies[ptyp]) AND(child[MeSH:noexp] OR adolescent[MeSH] OR adult[MeSH:noexp] OR mid-dle age[MeSH] OR (middle age[MeSH] OR aged[MeSH]) OR aged[MeSH]OR aged, 80 and over[MeSH]))))) NOT (((diarrhea AND morbidity AND (("2014/01/01"[PDat]: "2021/04/30"[PDat]) AND (Humans[Mesh]) AND (Clinical Trial[ptyp] ORMeta-Analysis[ptyp] OR Randomized Controlled Trial[ptyp] OR Review[ptyp]OR Clinical Trial, Phase I[ptyp] OR Clinical Trial, Phase II[ptyp] OR Clini-cal Trial, Phase III[ptyp] OR Clinical Trial, Phase IV[ptyp] OR ComparativeStudy[ptyp] OR Controlled Clinical Trial[ptyp] OR Corrected and Repub-lished Article[ptyp] OR English Abstract[ptyp] OR Evaluation Studies[ptyp]OR Journal Article[ptyp] OR Multicenter Study[ptyp] OR Research Support,N I H, Extramural[ptyp] OR Research Support, N I H, Intramural[ptyp] ORResearch Support, Non U S Gov't[ptyp] OR Research Support, U S Gov't,Non P H S[ptyp] OR Research Support, U S Gov't, P H S[ptyp] OR TwinStudy[ptyp] OR Validation Studies[ptyp]) AND (child[MeSH:noexp] OR ado-lescent[MeSH] OR adult[MeSH:noexp] OR middle age[MeSH] OR (middleage[MeSH] OR aged[MeSH]) OR aged[MeSH] OR aged, 80 and over[MeSH]))OR (diarrhea AND mortality AND (("2014/01/01"[PDat] : "2021/04/30"[PDat])AND (Humans[Mesh]) AND (Clinical Trial[ptyp] OR Meta-Analysis[ptyp]OR Randomized Controlled Trial[ptyp] OR Review[ptyp] OR Clinical Trial,Phase I[ptyp] OR Clinical Trial, Phase II[ptyp] OR Clinical Trial,

Phase III[ptyp] OR Clinical Trial, Phase IV[ptyp] OR Comparative Study[ptyp] OR Con-trolled Clinical Trial[ptyp] OR Corrected and Republished Article[ptyp] OREnglish Abstract[ptyp] OR Evaluation Studies[ptyp] OR Journal Article[ptyp]OR Multicenter Study[ptyp] OR Research Support, N I H, Extramural[ptyp]OR Research Support, N I H, Intramural[ptyp] OR Research Support, NonU S Gov't[ptyp] OR Research Support, U S Gov't, Non P H S[ptyp] ORResearch Support, U S Gov't, P H S[ptyp] OR Twin Study[ptyp] OR Val-idation Studies[ptyp]) AND (child[MeSH:noexp] OR adolescent[MeSH] ORadult[MeSH:noexp] OR middle age[MeSH] OR (middle age[MeSH] OR aged[MeSH])OR aged[MeSH] OR aged, 80 and over[MeSH]))) OR (diarrhea AND etiologyAND ((“2014/01/01”[PDat] : “2021/04/30”[PDat]) AND (Humans[Mesh])AND (Clinical Trial[ptyp] OR Meta-Analysis[ptyp] OR Randomized Con-trolled Trial[ptyp] OR Review[ptyp] OR Clinical Trial, Phase I[ptyp] OR Clin-ical Trial, Phase II[ptyp] OR Clinical Trial, Phase III[ptyp] OR Clinical Trial,Phase IV[ptyp] OR Comparative Study[ptyp] OR Controlled Clinical Trial[ptyp]OR Corrected and Republished Article[ptyp] OR English Abstract[ptyp] OREvaluation Studies[ptyp] OR Journal Article[ptyp] OR Multicenter Study[ptyp]OR Research Support, N I H, Extramural[ptyp] OR Research Support, NI H, Intramural[ptyp] OR Research Support, Non U S Gov't[ptyp] OR Re-search Support, U S Gov't, Non P H S[ptyp] OR Research Support, U SGov't, P H S[ptyp] OR Twin Study[ptyp] OR Validation Studies[ptyp]) AND(child[MeSH:noexp] OR adolescent[MeSH] OR adult[MeSH:noexp] OR mid-dle age[MeSH] OR (middle age[MeSH] OR aged[MeSH]) OR aged[MeSH]OR aged, 80 and over[MeSH]))))) AND cancer)) AND Traveler's Diarrhea))NOT (((((diarrhea AND morbidity AND ((“2014/01/01”[PDat] : “2021/04/30”[PDat])AND (Humans[Mesh]) AND (Clinical Trial[ptyp] OR Meta- Analysis[ptyp]OR Randomized Controlled Trial[ptyp] OR Review[ptyp] OR Clinical Trial,Phase I[ptyp] OR Clinical Trial, Phase II[ptyp] OR Clinical Trial, Phase III[ptyp]OR Clinical Trial, Phase IV[ptyp] OR Comparative Study[ptyp] OR Con-trolled Clinical Trial[ptyp] OR Corrected and Republished Article[ptyp] OREnglish Abstract[ptyp] OR Evaluation Studies[ptyp] OR Journal Article[ptyp]OR Multicenter Study[ptyp] OR Research Support, N I H, Extramural[ptyp]OR Research Support, N I H, Intramural[ptyp] OR Research Support, NonU S Gov't[ptyp] OR Research Support, U S Gov't, Non P H S[ptyp] ORResearch Support, U S Gov't, P H S[ptyp] OR Twin Study[ptyp] OR Val-idation Studies[ptyp]) AND (child[MeSH:noexp] OR adolescent[MeSH] ORadult[MeSH:noexp] OR middle age[MeSH] OR (middle age[MeSH] OR aged[MeSH]) OR aged[MeSH] OR aged, 80 and over[MeSH]))) OR (diarrhea AND mortal-ity AND ((“2014/01/01”[PDat] : “2021/04/30”[PDat]) AND (Humans[Mesh])AND (Clinical Trial[ptyp] OR Meta-Analysis[ptyp] OR Randomized Con-trolled Trial[ptyp] OR Review[ptyp] OR Clinical Trial, Phase I[ptyp] OR Clin-ical Trial, Phase II[ptyp] OR Clinical Trial, Phase III[ptyp] OR Clinical Trial,Phase IV[ptyp] OR Comparative Study[ptyp] OR Controlled Clinical Trial[ptyp]OR Corrected and Republished Article[ptyp] OR English Abstract[ptyp] OREvaluation Studies[ptyp] OR Journal Article[ptyp] OR Multicenter Study[ptyp]OR Research Support, N I H, Extramural[ptyp] OR Research Support, NI H, Intramural[ptyp] OR Research Support, Non U S Gov't[ptyp] OR Re-search Support, U S Gov't, Non P H S[ptyp] OR Research Support, U SGov't, P H S[ptyp] OR Twin Study[ptyp] OR Validation Studies[ptyp]) AND(child[MeSH:noexp] OR adolescent[MeSH] OR adult[MeSH:noexp] OR mid-dle age[MeSH] OR (middle age[MeSH] OR aged[MeSH]) OR aged[MeSH]OR aged, 80 and over[MeSH]))) OR (diarrhea AND etiology AND ((“2014/01/01”[PDat]: “2021/04/30”[PDat]) AND (Humans[Mesh]) AND (Clinical Trial[ptyp] ORMeta-Analysis[ptyp] OR Randomized Controlled Trial[ptyp] OR Review[ptyp]OR Clinical Trial, Phase I[ptyp] OR Clinical Trial, Phase II[ptyp] OR Clini-cal Trial, Phase III[ptyp] OR Clinical Trial, Phase IV[ptyp] OR ComparativeStudy[ptyp] OR Controlled Clinical Trial[ptyp] OR Corrected and Repub-lished Article[ptyp] OR English Abstract[ptyp] OR Evaluation

Studies[ptyp]OR Journal Article[ptyp] OR Multicenter Study[ptyp] OR Research Support,N I H, Extramural[ptyp] OR Research Support, N I H, Intramural[ptyp] ORResearch Support, Non U S Gov't[ptyp] OR Research Support, U S Gov't,Non P H S[ptyp] OR Research Support, U S Gov't, P H S[ptyp] OR TwinStudy[ptyp] OR Validation Studies[ptyp]) AND (child[MeSH:noexp] OR ado-lescent[MeSH] OR adult[MeSH:noexp] OR middle age[MeSH] OR (middleage[MeSH] OR aged[MeSH]) OR aged[MeSH] OR aged, 80 and over[MeSH])))NOT (((diarrhea AND morbidity AND (("2014/01/01"[PDat] : "2021/04/30"[PDat])AND (Humans[Mesh]) AND (Clinical Trial[ptyp] OR Meta-Analysis[ptyp]OR Randomized Controlled Trial[ptyp] OR Review[ptyp] OR Clinical Trial,Phase I[ptyp] OR Clinical Trial, Phase II[ptyp] OR Clinical Trial, Phase III[ptyp]OR Clinical Trial, Phase IV[ptyp] OR Comparative Study[ptyp] OR Con-trolled Clinical Trial[ptyp] OR Corrected and Republished Article[ptyp] OREnglish Abstract[ptyp] OR Evaluation Studies[ptyp] OR Journal Article[ptyp]OR Multicenter Study[ptyp] OR Research Support, N I H, Extramural[ptyp]OR Research Support, N I H, Intramural[ptyp] OR Research Support, NonU S Gov't[ptyp] OR Research Support, U S Gov't, Non P H S[ptyp] OR Research Support, U S Gov't, P H S[ptyp] OR Twin Study[ptyp] OR Val-idation Studies[ptyp]) AND (child[MeSH:noexp] OR adolescent[MeSH] ORadult[MeSH:noexp] OR middle age[MeSH] OR (middle age[MeSH] OR aged[MeSH])OR aged[MeSH] OR aged, 80 and over[MeSH]))) OR (diarrhea AND mortal-ity AND (("2014/01/01"[PDat] : "2021/04/30"[PDat]) AND (Humans[Mesh])AND (Clinical Trial[ptyp] OR Meta-Analysis[ptyp] OR Randomized Con-trolled Trial[ptyp] OR Review[ptyp] OR Clinical Trial, Phase I[ptyp] OR Clin-ical Trial, Phase II[ptyp] OR Clinical Trial, Phase III[ptyp] OR Clinical Trial,Phase IV[ptyp] OR Comparative Study[ptyp] OR Controlled Clinical Trial[ptyp]OR Corrected and Republished Article[ptyp] OR English Abstract[ptyp] OREvaluation Studies[ptyp] OR Journal Article[ptyp] OR Multicenter Study[ptyp]OR Research Support, N I H, Extramural[ptyp] OR Research Support, NI H, Intramural[ptyp] OR Research Support, Non U S Gov't[ptyp] OR Re-search Support, U S Gov't, Non P H S[ptyp] OR Research Support, U SGov't, P H S[ptyp] OR Twin Study[ptyp] OR Validation Studies[ptyp]) AND(child[MeSH:noexp] OR adolescent[MeSH] OR adult[MeSH:noexp] OR mid-dle age[MeSH] OR (middle age[MeSH] OR aged[MeSH]) OR aged[MeSH]OR aged, 80 and over[MeSH]))) OR (diarrhea AND etiology AND (("2014/01/01"[PDat]: "2021/04/30"[PDat]) AND (Humans[Mesh]) AND (Clinical Trial[ptyp] ORMeta-Analysis[ptyp] OR Randomized Controlled Trial[ptyp] OR Review[ptyp]OR Clinical Trial, Phase I[ptyp] OR Clinical Trial, Phase II[ptyp] OR Clini-cal Trial, Phase III[ptyp] OR Clinical Trial, Phase IV[ptyp] OR ComparativeStudy[ptyp] OR Controlled Clinical Trial[ptyp] OR Corrected and Repub-lished Article[ptyp] OR English Abstract[ptyp] OR Evaluation Studies[ptyp]OR Journal Article[ptyp] OR Multicenter Study[ptyp] OR Research Support,N I H, Extramural[ptyp] OR Research Support, N I H, Intramural[ptyp] ORResearch Support, Non U S Gov't[ptyp] OR Research Support, U S Gov't,Non P H S[ptyp] OR Research Support, U S Gov't, P H S[ptyp] OR TwinStudy[ptyp] OR Validation Studies[ptyp]) AND (child[MeSH:noexp] OR ado-lescent[MeSH] OR adult[MeSH:noexp] OR middle age[MeSH] OR (middleage[MeSH] OR aged[MeSH]) OR aged[MeSH] OR aged, 80 and over[MeSH])))AND cancer)) NOT ((((diarrhea AND morbidity AND (("2014/01/01"[PDat]: "2021/04/30"[PDat]) AND (Humans[Mesh]) AND (Clinical Trial[ptyp] ORMeta-Analysis[ptyp] OR Randomized Controlled Trial[ptyp] OR Review[ptyp]OR Clinical Trial, Phase I[ptyp] OR Clinical Trial, Phase II[ptyp] OR Clini-cal Trial, Phase III[ptyp] OR Clinical Trial, Phase IV[ptyp] OR ComparativeStudy[ptyp] OR Controlled Clinical Trial[ptyp] OR Corrected and Repub-lished Article[ptyp] OR English Abstract[ptyp] OR Evaluation Studies[ptyp]

Appendix A. Appendix A: Search strings69OR Journal Article[ptyp] OR Multicenter Study[ptyp] OR Research Support,N I H, Extramural[ptyp] OR Research Support, N I H, Intramural[ptyp]

ORResearch Support, Non U S Gov't[ptyp] OR Research Support, U S Gov't,Non P H S[ptyp] OR Research Support, U S Gov't, P H S[ptyp] OR TwinStudy[ptyp] OR Validation Studies[ptyp]) AND (child[MeSH:noexp] OR ado-lescent[MeSH] OR adult[MeSH:noexp] OR middle age[MeSH] OR (middleage[MeSH] OR aged[MeSH]) OR aged[MeSH] OR aged, 80 and over[MeSH]))OR (diarrhea AND mortality AND (("2014/01/01"[PDat] : "2021/04/30"[PDat])AND (Humans[Mesh]) AND (Clinical Trial[ptyp] OR Meta-Analysis[ptyp]OR Randomized Controlled Trial[ptyp] OR Review[ptyp] OR Clinical Trial,Phase I[ptyp] OR Clinical Trial, Phase II[ptyp] OR Clinical Trial, Phase III[ptyp]OR Clinical Trial, Phase IV[ptyp] OR Comparative Study[ptyp] OR Con-trolled Clinical Trial[ptyp] OR Corrected and Republished Article[ptyp] OREnglish Abstract[ptyp] OR Evaluation Studies[ptyp] OR Journal Article[ptyp]OR Multicenter Study[ptyp] OR Research Support, N I H, Extramural[ptyp]OR Research Support, N I H, Intramural[ptyp] OR Research Support, NonU S Gov't[ptyp] OR Research Support, U S Gov't, Non P H S[ptyp] ORResearch Support, U S Gov't, P H S[ptyp] OR Twin Study[ptyp] OR Val-idation Studies[ptyp]) AND (child[MeSH:noexp] OR adolescent[MeSH] ORadult[MeSH:noexp] OR middle age[MeSH] OR (middle age[MeSH] OR aged[MeSH])OR aged[MeSH] OR aged, 80 and over[MeSH]))) OR (diarrhea AND etiologyAND (("2014/01/01"[PDat] : "2021/04/30"[PDat]) AND (Humans[Mesh])AND (Clinical Trial[ptyp] OR Meta-Analysis[ptyp] OR Randomized Con-trolled Trial[ptyp] OR Review[ptyp] OR Clinical Trial, Phase I[ptyp] OR Clin-ical Trial, Phase II[ptyp] OR Clinical Trial, Phase III[ptyp] OR Clinical Trial,Phase IV[ptyp] OR Comparative Study[ptyp] OR Controlled Clinical Trial[ptyp]OR Corrected and Republished Article[ptyp] OR English Abstract[ptyp] OREvaluation Studies[ptyp] OR Journal Article[ptyp] OR Multicenter Study[ptyp]OR Research Support, N I H, Extramural[ptyp] OR Research Support, NI H, Intramural[ptyp] OR Research Support, Non U S Gov't[ptyp] OR Re-search Support, U S Gov't, Non P H S[ptyp] OR Research Support, U SGov't, P H S[ptyp] OR Twin Study[ptyp] OR Validation Studies[ptyp]) AND(child[MeSH:noexp] OR adolescent[MeSH] OR adult[MeSH:noexp] OR mid-dle age[MeSH] OR (middle age[MeSH] OR aged[MeSH]) OR aged[MeSH]OR aged, 80 and over[MeSH])))) NOT (((diarrhea AND morbidity AND (("2014/01/01"[PDat]: "2021/04/30"[PDat]) AND (Humans[Mesh]) AND (Clinical Trial[ptyp] ORMeta-Analysis[ptyp] OR Randomized Controlled Trial[ptyp] OR Review[ptyp]

Appendix A. Appendix A: Search strings70OR Clinical Trial, Phase I[ptyp] OR Clinical Trial, Phase II[ptyp] OR Clini-cal Trial, Phase III[ptyp] OR Clinical Trial, Phase IV[ptyp] OR ComparativeStudy[ptyp] OR Controlled Clinical Trial[ptyp] OR Corrected and Repub-lished Article[ptyp] OR English Abstract[ptyp] OR Evaluation Studies[ptyp]OR Journal Article[ptyp] OR Multicenter Study[ptyp] OR Research Support,N I H, Extramural[ptyp] OR Research Support, N I H, Intramural[ptyp] ORResearch Support, Non U S Gov't[ptyp] OR Research Support, U S Gov't,Non P H S[ptyp] OR Research Support, U S Gov't, P H S[ptyp] OR TwinStudy[ptyp] OR Validation Studies[ptyp]) AND (child[MeSH:noexp] OR ado-lescent[MeSH] OR adult[MeSH:noexp] OR middle age[MeSH] OR (middleage[MeSH] OR aged[MeSH]) OR aged[MeSH] OR aged, 80 and over[MeSH]))OR (diarrhea AND mortality AND (("2014/01/01"[PDat] : "2021/04/30"[PDat])AND (Humans[Mesh]) AND (Clinical Trial[ptyp] OR Meta-Analysis[ptyp]OR Randomized Controlled Trial[ptyp] OR Review[ptyp] OR Clinical Trial,Phase I[ptyp] OR Clinical Trial, Phase II[ptyp] OR Clinical Trial, Phase III[ptyp]OR Clinical Trial, Phase IV[ptyp] OR Comparative Study[ptyp] OR Con-trolled Clinical Trial[ptyp] OR Corrected and Republished Article[ptyp] OREnglish Abstract[ptyp] OR Evaluation Studies[ptyp] OR Journal Article[ptyp]OR Multicenter Study[ptyp] OR Research Support, N I H, Extramural[ptyp]OR Research Support, N I H, Intramural[ptyp] OR Research Support, NonU S Gov't[ptyp] OR Research Support, U S Gov't, Non P H S[ptyp] ORResearch Support, U S Gov't, P H S[ptyp] OR Twin Study[ptyp] OR Val-idation Studies[ptyp]) AND

(child[MeSH:noexp] OR adolescent[MeSH] ORadult[MeSH:noexp] OR middle age[MeSH] OR (middle age[MeSH] OR aged[MeSH])OR aged[MeSH] OR aged, 80 and over[MeSH]))) OR (diarrhea AND etiologyAND ((“2014/01/01”[PDat] : “2021/04/30”[PDat]) AND (Humans[Mesh])AND (Clinical Trial[ptyp] OR Meta-Analysis[ptyp] OR Randomized Con-trolled Trial[ptyp] OR Review[ptyp] OR Clinical Trial, Phase I[ptyp] OR Clin-ical Trial, Phase II[ptyp] OR Clinical Trial, Phase III[ptyp] OR Clinical Trial,Phase IV[ptyp] OR Comparative Study[ptyp] OR Controlled Clinical Trial[ptyp]OR Corrected and Republished Article[ptyp] OR English Abstract[ptyp] OREvaluation Studies[ptyp] OR Journal Article[ptyp] OR Multicenter Study[ptyp]OR Research Support, N I H, Extramural[ptyp] OR Research Support, NI H, Intramural[ptyp] OR Research Support, Non U S Gov’t[ptyp] OR Re-search Support, U S Gov’t, Non P H S[ptyp] OR Research Support, U SGov’t, P H S[ptyp] OR Twin Study[ptyp] OR Validation Studies[ptyp]) AND(child[MeSH:noexp] OR adolescent[MeSH] OR adult[MeSH:noexp] OR mid-dle age[MeSH] OR (middle age[MeSH] OR aged[MeSH]) OR aged[MeSH] OR aged, 80 and over[MeSH]))))) AND cancer)) AND Traveler’s Diarrhea))AND Case report)

Supplementary Search String 2: Search String for SCOPUS

TITLE-ABS-KEY ("diarrhea") OR TITLE-ABS-KEY("diarrhoea") AND (TITLE-ABS-KEY ("gastroenteritis") OR TITLE-ABS-KEY("mortality")) OR (TITLE-ABS-KEY ("etiology") OR TITLE-ABS-KEY ("pathogen") OR TITLE-ABS-KEY ("incidence") OR TITLE-ABS-KEY ("morbidity") OR TITLE-ABS-KEY("cause of death") OR TITLE-ABS-KEY("diarrhea")) AND PUBYEAR > 2013AND NOT DOCTYPE (cp) AND NOT DOCTYPE (ed) AND NOT DOC-TYPE (le) AND NOT DOCTYPE (no) AND KEY ("human") AND NOTPUBYEAR = 2022 AND NOT TITLE-ABS-KEY ("Case report") AND NOT TITLE-ABS-KEY ("hospitalized acquired diarrhea") AND NOT TITLE-ABS-KEY ("antibiotic associated diarrhea") AND NOT TITLE-ABS-KEY ("cancerpatient") AND NOT TITLE-ABS-KEY ("traveler") AND NOT TITLE-ABS-KEY ("refugees") AND NOT TITLE-ABS-KEY ("migrants") OR TITLE-ABS-KEY ("prospective study") AND TITLE-ABS-KEY (diarrhea AND sample*) AND TITLE-ABS-KEY (diarrhea AND agent) AND NOT (ABS ("chil-dren under 5") OR ABS ("children below 5") OR ABS ("children < 5")OR ABS ("children under five") OR ABS ("children below five")) OR ABS(daycare* AND outbreak*) OR ABS (adult AND care* AND outbreak*) AND NOT (ABS (recall AND period AND below 4 week*) OR ABS(recall AND period AND under 4 week*) OR ABS (recall AND periodAND below AND four AND week*) OR ABS (recall AND period ANDunder AND four AND week*)) AND NOT TITLE-ABS-KEY("cross sec-tional study") AND NOT TITLE-ABS-KEY("animal") AND NOT TITLE-ABS-KEY("neonatal") AND NOT TITLE-ABS-KEY("COVID-19") AND NOT TITLE-ABS-KEY("infant") AND NOT TITLE-ABS-KEY("SARS-CoV-2") AND NOTTITLE-ABS-KEY("cancer") AND NOT TITLE-ABS-KEY("HIV mortality") ANDNOT TITLE-ABS-KEY("diabetes") AND NOT TITLE-ABS-KEY("dysentery")AND NOT TITLE-ABS-KEY("under-five") AND NOT TITLE-ABS-KEY("childbirth")AND NOT TITLE-ABS-KEY("animal") AND (LIMIT-TO (AFFILCOUNTRY,"SouthAfrica") OR LIMIT-TO (AFFILCOUNTRY,"Egypt") OR LIMIT-TO (AF-FILCOUNTRY,"Nigeria") OR LIMIT-TO (AFFILCOUNTRY,"Ethiopia") ORLIMIT-TO (AFFILCOUNTRY,"Kenya") OR LIMIT-TO (AFFILCOUNTRY,"Uganda") OR LIMIT-TO (AFFILCOUNTRY,"Ghana") OR LIMIT-TO (AFFILCOUN-TRY,"Tunisia") OR LIMIT-TO (AFFILCOUNTRY,"Morocco") OR LIMIT-TO (AFFILCOUNTRY,"Cameroon") OR LIMIT-TO (AFFILCOUNTRY,"Malawi") OR LIMIT-TO (AFFILCOUNTRY,"Algeria") OR LIMIT-TO (AFFILCOUN-TRY,"Zambia") OR LIMIT-TO (AFFILCOUNTRY,"Zimbabwe") OR LIMIT-TO (AFFILCOUNTRY,"Burkina Faso") OR LIMIT-TO (AFFILCOUNTRY,"Sudan") OR LIMIT-TO (AFFILCOUNTRY,"Senegal") OR LIMIT-TO (AFFILCOUN-TRY,"Mozambique") OR LIMIT-TO (AFFILCOUNTRY,"Congo") OR LIMIT-TO (AFFILCOUNTRY,"Rwanda") OR LIMIT-TO (AFFILCOUNTRY,"Coted'Ivoire") OR LIMIT-TO (AFFILCOUNTRY,"Benin") OR LIMIT-TO (AFFIL-COUNTRY,"Botswana") OR LIMIT-TO (AFFILCOUNTRY,"Gambia") ORLIMIT-TO (AFFILCOUNTRY,"Mali") OR LIMIT-TO (AFFILCOUNTRY,"Madagascar") OR LIMIT-TO (AFFILCOUNTRY,"Democratic Republic Congo") OR LIMIT-TO (AFFILCOUNTRY,"Sierra Leone") OR LIMIT-TO (AFFILCOUNTRY,"Namibia") OR LIMIT-TO (AFFILCOUNTRY,"Libyan Arab Jamahiriya") OR LIMIT-TO (AFFILCOUNTRY,"Gabon") OR LIMIT-TO (AFFILCOUNTRY,"Togo")OR LIMIT-TO (AFFILCOUNTRY,"Guinea-Bissau") OR LIMIT-TO (AFFIL-COUNTRY,"Niger") OR LIMIT-TO (AFFILCOUNTRY,"Liberia") OR LIMIT-TO (AFFILCOUNTRY,"Angola"))

Supplementary Table S1: Search String for Web of Science

Search terms and combinations (≠1 OR ≠2 OR ≠3 OR ≠4)			
≠1	Diarrhea* OR diarrhoea*	AND	incid* OR occur*
≠2	Diarrhea* OR diarrhoea*	AND	mortal* OR gastroent*
≠3	Diarrhea* OR diarrhoea*	AND	etiol* OR aetiol* OR pathog* OR cause of death
≠4	Diarrhea* OR diarrhoea*	AND	child* OR young* OR adolescent* OR infant*

Supplementary Table S2: Characteristics of the studies included in the review (n = 38).

	Year(s) of study	Country	African Region	Area Classification	Type of study	Study design	Age Group	Diagnostic method(s)	Total number of pathogens investigated	Pathogens investigated (that are relevant for this study)	Rotavirus vaccine introduced (as of study introduction)
Ouédraogo et al (2016)	2011-2012	Burkina Faso	Western Africa	Urban	Out-patient	Prospective case-control	0-5 years	PCR (end-point or RT)	5	Astrovirus, rotavirus, norovirus	No
Japhet et al (2019)	2012-2013	Nigeria	Western Africa	Mixed	Out-patient	Case-control	0-5 years	PCR	5	Rotavirus, norovirus, astrovirus	No
Arowolo et al (2019)	2015-2017	Nigeria	Western Africa	Urban	In-patient	Cross-sectional	0-5 years	PCR	4	Rotavirus, norovirus, astrovirus	No
Gasparinho et al (2016)	2012-2013	Angola	Central Africa	Urban	In-patient and out-patient	Cross-sectional	0-5 years	Antigen Rapid Test, ELISA, PCR, Microscopy, Culture	15	*Cryptosporidium* spp., rotavirus, *G. lamblia*, EAEC, ETEC, astrovirus, *E. histolytica*	No
Hungerford et al (2020)	2012-2015	Malawi	Southern Africa	Unknown	Community setting	Case-control	0-5 years	RT-PCR	29	*Campylobacter* spp., *Cryptosporidium* spp., *G. lamblia*, rotavirus, astrovirus, norovirus	Yes
Acacio et al (2019)	2007-2012	Mozambique	Eastern Africa	Urban	Out-patient, in-patient	Case-control	0-5 years	Serological screening, PCR	26	ETEC, EAEC, EPEC, *Shigella* spp., rotavirus, norovirus,	No

										V. cholerae, *Salmonella* spp., *Cryptosporidium* spp., *G. lamblia*, *E. histolytica*, *Campylobacter* spp., astrovirus	
Nhampossa et al (2015)	2007-2011	Mozambique	Eastern Africa	Rural	In-patient, out-patient, and community study	Prospective case-control	0-5 years	Multiplex PCR, RT-PCR, ELISA, Immunoassays	21	*G. lamblia*, *Cryptosporidium* spp., *E. histolytica*, rotavirus, norovirus, astrovirus, ETEC, EAEC, EPEC, *Shigella* spp., *Salmonella* spp., *V. cholerae*, *Campylobacter* spp.	No
Iturriza-Gómara et al (2019)	2013-2016	Malawi	Southern Africa	Urban	Community setting, in-patient	Case-control	0-5 years	RT-PCR	31	EAEC, rotavirus, *Cryptosporidium* spp., ETEC, EPEC, *Campylobacter* spp., EIEC, norovirus, *G. lamblia*, *Salmonella* spp., astrovirus, *E. histolytica*, *V. cholerae*, STEC	Yes

Platts-Mills et al (2015)	2009-2012	South Africa	Southern Africa	Unknown	Community-setting	Cohort study	0-2 years	Multiplex PCR	25	*Campylobacter* spp., *G. lamblia*, EAEC, norovirus, ETEC, astrovirus, rotavirus, EPEC, EPEC, EIEC, STEC, *V. cholerae*	Yes
Zimmermann et al (2019)	2007-2011	Mali, Mozambique, Kenya, The Gambia	Western Africa, Eastern Africa	Unknown	In-patient and out-patient	Retrospective cohort study	0-5 years	Serological screening, PCR	7	*Shigella* spp., *Campylobacter* spp., *Cryptosporidium* spp., norovirus, rotavirus, ETEC, *V. cholerae*	No
Mayindou et al (2019)	2012-2013	Democratic Republic of Congo	Central Africa	Urban	In-patient	Cross-sectional	0-5 years	ELISA, RT-PCR	2	Rotavirus, norovirus	No
Chuckwu et al (2020)	2016-2017	South Africa	Southern Africa	Mixed	Community setting	Cross-sectional	0-5 years	RT-PCR	5	*Campylobacter*, rotavirus, norovirus	Yes
El Qazoui et al (2014)	2011	Morocco	Northern Africa	Urban	In-patient	Cross-sectional	0-5 years	RT-multiplex PCR, RT-PCR	2	Rotavirus, norovirus	Yes
Ashie et al (2017)	2012-2014	Ghana	Western Africa	Mixed	Out-patient, in-patient	Case-control	0-5 years	Microscopy, immunoassays	8	Rotavirus, *Shigella* spp., *Salmonella* spp., *G. lamblia*	Yes
Msolo et al (2020)	2017-2018	South Africa	Southern Africa	Rural	In-patient	Cross-sectional	0-40 years	Immunoassays	2	Rotavirus, *Cryptosporidium* spp.	Yes

El-Shabrawi et al (2015)	2007-2009	Egypt	Northern Africa	Urban	Out-patient	Case-control	0-5 years	ELISA	6	ETEC, *Campylobacter* spp., *Shigella* spp., *Salmonella* spp., *Cryptosporidium* spp., rotavirus	No
Mansour et al (2014)	2004-2007	Egypt	Northern Africa	Rural	Community setting	Cohort study	0-2 years	ELISA	4	ETEC, *Campylobacter* spp., *Shigella* spp., rotavirus	No
Gosselin et al (2018)	2009-2011	Tanzania	Eastern Africa	Urban	Community setting	Prospective randomized trial	0-2 years	PCR	15	*Cryptosporidium* spp., rotavirus, *Shigella* spp., EIEC, *Campylobacter* spp., EPEC, ETEC	No
Imade et al (2015)	2011-2012	Nigeria	Western Africa	Mixed	Out-patient	Cross-sectional	0-3 years	Immunoassays	3	Rotavirus, norovirus	No
Lompo et al (2021)	2012-2014	Burkina Faso	Western Africa	Rural	In-patient	Cross-sectional	0-5 years	Immunoassay	6	EPEC, *G. lamblia*, *Shigella* spp., rotavirus	Yes
Onanuga et al (2014)	2008-2009	Nigeria	Western Africa	Urban	Out-patient	Prospective cohort	0-5 years	PCR	1*	EPEC, ETEC, EHEC, EAEC, EIEC, STEC	-
Odetoyin et al (2016)	2008-2011	Nigeria	Western Africa	Unknown	Community setting	Cross-sectional	0-46 years	Multiplex PCR	1*	EPEC, EAEC, ETEC, STEC, EHEC	-

Lijima et al (2017)	2007-2009	Kenya	Eastern Africa	Urban	Out-patient	Cross-sectional	0-5 years	RT-PCR	1*	EPEC, EAEC, ETEC, STEC, EHEC, EIEC	-
Hassan et al (2014)	2004-2007	Egypt	Northern Africa	Rural	Community setting	Prospective cohort	0-2 years	ELISA	4	*Shigella* spp., *Campylobacter* spp., ETEC	-
Njuguna et al (2016)	2012	Kenya	Eastern Africa	Mixed	In-patient and out-patient	Matched case-control	All ages	Microscopy, PCR	9	*Shigella* spp., *Salmonella* spp., *G. lamblia*, *E. histolytica*	-
Terfassa, Jida (2018)	2015-2016	Ethiopia	Eastern Africa	Rural	Out-patient	Cross-sectional	All ages	Immunoassay	2	*Salmonella* spp., *Shigella* spp.	-
Ferreira et al (2020)	2012-2013	Mozambique	Eastern Africa	Urban	In-patient	Cross-sectional	0-60 years	Microscopy	10	*E. histolytica*, *Cryptosporidium* spp.	-
Bauhofer et al (2020)	2014-2018	Mozambique	Eastern Africa	Urban	In-patient and out-patient	Cross-sectional	0-14 years	Immunoassay	3	*Cryptosporidium* spp., *G. lamblia*, *E. histolytica*	-
von Huth et al (2019)	2015-2017	Guinea-Bissau	Western Africa	Urban	Community setting	Cohort	2-7 years	Microscopy	14	*G. lamblia*, *E. histolytica*	-
Garzón et al (2017)	2013-2015	Sáo Tomé and Príncipe	Western Africa	Mixed	Community setting	Cross-sectional	0-5 years	Microscopy, ELISA, PCR	8	*G. lamblia*, *Cryptosporidium* spp., *E. histolytica*	-
Muadica et al (2021)	2017-2019	Mozambique	Eastern Africa	Mixed	Community setting	Prospective cross-sectional	3-14 years	PCR	3	*Cryptosporidium* spp.	-

Ramos et al (2014)	2007-2012	Ethiopia	Eastern Africa	Rural	In-patient	Retrospective observational study	All ages	Microscopy	9	*G. lamblia*, *E. histolytica*	-
Tellevik et al (2015)	2010-2011	Tanzania	Eastern Africa	Urban	Out-patient	Case-control	0-5 years	PCR	2	*G. lamblia*, *E. histolytica*	-
Trainor et al (2016)	1997-2007	Malawi	Southern Africa	Urban	In-patient	Cohort	0-5 years	PCR	4	ETEC	-
Prah et al (2021)	2016-2018	Ghana	Western Africa	Unknown	Out-patient	Prospective case-control	0-5 years	PCR	1*	EIEC, EHEC, EPEC, STEC, ETEC, EAEC	-
Omolajaiye et al (2020)	2015-2017	South Africa	Southern Africa	Unknown	In-patient	Prospective cross-sectional	0-12 years	PCR	1*	EHEC, EIEC, EPEC	-
Naguib et al (2018)	2015-2016	Egypt	Northern Africa	Mixed	Community setting	Cross-sectional	0-8 years	PCR-RFLP	2	*Cryptosporidium* spp.	-
Bitilinyu-Bangoh et al (2019)	2014-2015	Malawi, Kenya	Southern Africa, Eastern Africa	Unknown	In-patient	Randomised controlled trial	0-5 years	Multiplex PCR	3	*E. histolytica*, *Cryptosporidium* spp.	-

*The study passed the inclusion criteria if it presented more than one type of diarrheagenic *E. coli*.

Supplementary Table S3: Detailed description of the studies reporting incidence of diarrhea meeting inclusion criteria, stratified by age group and/or study setting

	Pathogens etiologies reported	**Sub-group specification**	**Total population (t)**	**Rotavirus (n)**	**Norovirus (n)**	**Astrovirus (n)**	***Cryptosporidium* spp. (n)**	***E. histolytica* (n)**	***G. lamblia* (n)**	***Campylobacter* spp.**	**EAEC (n)**	**EPEC (n)**	**EHEC (n)**	**ETEC (n)**	**EIEC (n)**	**STEC (n)**	***Salmonella* spp. (n)**	***Shigella* spp. (n)**	***V. cholerae* (n)**	***Other (n)***	***Unknown (n)***
Ouédraogo et al (2016)	Astrovirus, rotavirus, norovirus	-	263	167	48	13	-	-	-	-	-	-	-	-	-	-	-	-	-	111	-
Japhet et al (2019)	Astrovirus, rotavirus, norovirus	0-5 months	21	20	1	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		6-11 months	21	14	6	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		12-23 months	9	6	0	3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		24-35 months	1	1	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

		All ages (0-35 month)	103	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	-
Zimmermann et al (2019	*Shigella* spp., *Campylobacter* spp., *Cryptosporidium* spp., norovirus, rotavirus, ETEC, *V. cholerae*	The Gambia	1933	318 (16.5%)	189 (9.8%)	-	233 (12.1%)	-	-	39 (2%)	-	-	-	220 (11.4%)	-	-	-	162 (8.4%)	0 (0%)	-	-
		Kenya	1778	252 (14.2%)	89 (5%)	-	196 (11%)	-	-	171 (9.6%)	-	-	-	176 (9.9%)	-	-	-	130 (7.3%)	7 (0.4%)	-	-
		Mali	3404	417 (12.3%)	77 (2.3%)	-	337 (9.9%)	-	-	52 (1.5%)	-	-	-	176 (5.2%)	-	-	-	51 (1.5%)	0 (0%)	-	-
		Mozambique	1217	342 (28.1%)	29 (2.4%)	-	193 (15.9%)	-	-	22 (1.8%)	-	-	-	119 (9.8%)	-	-	-	57 (4.7%)	12 (1%)	-	-
Arowolo et al (2019)	Rotavirus, astrovirus, norovirus	-	175	29	9	34	-	-	-	-	-	-	-	-	-	-	-	-	-	9	-

Gasparinho et al (2016)	*Cryptosporidium* spp., rotavirus, *G. lamblia*, EAEC, ETEC, astrovirus, *E. histolytica*	-	342 (rotavirus), 337 (*Cryptosporidium* spp.), 338 (*G. lamblia*), 274 (astrovirus), 341 (*E. histolytica*), 301 (EAEC, ETEC), 344 (unknown)	86	-	7	101	1	73	-	12	-	-	7	-	-	-	-	-	82	115
Hungerford et al. (2014)	*Campylobacter* spp., *Cryptosporidium* spp., *G. lamblia*, rotavirus, astrovirus, norovirus	Out-patient	527	0 (0%)	-	58 (11%)	11 (2%)	-	105 (20%)	190 (36%)	-	-	-	-	-	-	-	-	-	-	-
		In-patient	684	130 (19%)	-	0 (0%)	185 (27%)	-	48 (7%)	150 (22%)	-	-	-	-	-	-	-	-	-	-	-
		In-patient (0-5 months)	72	-	11	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		Out-patient (0-5 months)	30	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

		In-patient (6-11 months)	331	-	44	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		Out-patient (6-11 months)	339	-	30	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		In-patient (12-23 months)	219	-	24	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		Out-patient (12-23 months)	192	-	8	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		In-patient (24-60 months)	61	-	4	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		Out-patient (24-60 months)	70	-	5	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Acacio et al (2019)	ETEC, EAEC, *Shigella* spp., rotavirus, norovirus, *V. cholerae*, *Salmonella* spp., *Cryptosporidium* spp., *G. lamblia*, *E. histolytica*, *Campylobacter* spp., astrovirus	In-patient	14 (ETEC), 69 (EAEC, *V. cholerae*, *Shigella* spp., rotavirus, norovirus, astrovirus, *Cryptosporidium* spp., *E. histolytica*, *Campylobacter* spp., *G. lamblia*, *Salmonella* spp., Other)	15	1	3	26	9	10	2	15	-	-	5	-	-	0	3	1	1	-
		Out-patient	172 (ETEC), 752 (EAEC, *Shigella* spp., *Campylobacter* spp., *V. cholerae*, *Salmonella* spp.), 751 (rotavirus, norovirus, astrovirus, *Cryptosporidium* spp.,*G. lamblia*, Other), 750 (*E. histolytica*)	251	30	10	121	75	133	35	210	-	-	46	-	-	7	43	12	92	-
Nhampossa et al (2015)	*G. lamblia*, *Cryptosporidium* spp., *E. histolytica*, rotavirus,	0-11 months, in-patient	431	182	19	7	84	39	41	24	150	43	-	20	-	-	6	6	4	-	-

	norovirus, astrovirus, ETEC, EAEC, EPEC, *Shigella* spp., *Salmonella* spp., *V. cholerae*, *Campylobacter* spp.	0-11 months, out-patient	861	139	38	11	86	79	152	0	273	67	-	19	-	-	6	1	1	-	-
		12-23 months, in-patient	233	52	10	6	44	26	64	9	60	17	-	29	-	-	2	18	9	-	-
		12-23 months, out-patient	502	91	25	10	46	52	228	14	92	35	-	16	-	-	0	2	0	-	-
		24-60 months, in-patient	120	12	4	1	11	15	42	0	21	5	-	8	-	-	-	20	-	-	-
		24-60 months, out-patient	232	27	12	4	18	28	115	2	35	13	-	12	-	-	-	0	-	-	-
		In-patient (All age-groups)	431	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	25	-

		Out-patient (All age-groups)	861	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	54	-
Iturriza-Gómara et al (2019)	Rotavirus, *Cryptosporidium* spp., ETEC, EPEC, *Campylobacter* spp., norovirus, *G. lamblia*, *Salmonella* spp., astrovirus, *E. histolytica*, *V. cholerae*, STEC	In-patient	684	237	83	12	190	10	50	113	-	123	-	145	-	5	30	108	9	368	43
		Out-patient	527	8	45	13	43	1	73	102	-	45	-	45	-	1	5	30	0	121	-
Platts-Mills et al (2015)	*Campylobacter* spp., *G. lamblia*, EAEC, norovirus, ETEC, astrovirus, rotavirus, EPEC, EPEC, EIEC, STEC, *V. cholerae*	0-11 months	84	2 (2.4%)	44 (9.5%)	2 (2.4%)	-	-	-	24 (28.6%)	22 (26.2%)	3 (3.6%)	-	5 (4.8%)	-	-	-	-	-	3 (3.6%)	-
		12-24 months	73	2 (2.7%)	29 (39.7%)	3 (4.1%)	-	-	15 (20.5%)	13 (17.8%)	19 (26.0%)	2 (2.7%)	-	-	-	3 (4.1%)	-	-	-	5 (6.8%)	-
Mayindou et al (2019)	Rotavirus	-	655	226	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Chuckwu et al (2016)	*Campylobacter* spp., rotavirus, norovirus	-	505	118	101	-	-	-	-	254	-	-	-	-	-	-	-	-	-	80	-
El Qazoui et al (2014)	Rotavirus, norovirus	-	335	89	42	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Ashie et al (2017)	Rotavirus, *Shigella* spp., *Salmonella* spp., *G. lamblia*	0-12 months	155	16	-	-	-	-	-	-	-	-	-	-	-	-	7	5	-	-	-
		13-24 months	132	42	-	-	-	-	-	-	-	-	-	-	-	-	2	8	-	-	-
		25-60 months	60	14	-	-	-	-	-	-	-	-	-	-	-	-	11	3	-	-	-
		0-60 months (group 1)	107	-	-	-	-	-	5	-	-	-	-	-	-	-	-	-	-	18	-

		0-60 months (group 2)	240	-	-	-	-	-	7	-	-	-	-	-	-	-	-	-	-	32	-
Msolo et al (2020)	Rotavirus, *Cryptosporidium* spp.	-	53	19	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	-
El-Shabrawi et al (2015)	ETEC, *Campylobacter* spp., *Shigella* spp., *Salmonella* spp., *Cryptosporidium* spp., rotavirus	0-6 months	160	19	-	-	6	-	-	7	-	-	-	11	-	-	3	3	-	-	-
		7-12 months	105	13	-	-	6	-	-	2	-	-	-	5	-	-	1	3	-	-	-
		13-24 months	66	6	-	-	2	-	-	4	-	-	-	8	-	-	1	3	-	-	-
		25-60 months	25	0	-	-	0	-	-	0	-	-	-	1	-	-	0	1	-	-	-

Mansour et al (2014)	ETEC, *Campylobacter* spp., *Shigella* spp., rotavirus	-	4001	151	-	-	-	-	-	238	-	-	-	422	-	-	-	40	-	-	-
Gosselin et al (2018)	*Cryptosporidium* spp., rotavirus, *Shigella* spp., EIEC, *Campylobacter* spp., EPEC, ETEC	-	123	11	-	-	9	-	-	3	-	2	-	3	-	-	-	7	-	35	52
Imade et al (2015)	Rotavirus, norovirus	0-6 months	63	20	32	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		7-12 months	82	31	48	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		13-18 months	35	7	8	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		19-24 months	26	4	5	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

		25-30 months	11	1	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		31-36 months	6	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		0-36 months	223	63	8	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Lompo et al (2021)	EPEC, *G. lamblia*, *Shigella* spp., rotavirus	-	191	64 (33·3%)	-	-	-	-	87 (45·65%)	-	-	11 (6%)	-	-	-	-	-	15 (8%)	-	-	-
Onanuga et al (2014)	EPEC, ETEC, EHEC, EAEC, EIEC, STEC	-	201	-	-	-	-	-	-	-	21	9	-	11	1	19	-	-	-	-	-
Odetoyin et al (2016)	EPEC, EAEC, ETEC, STEC, EHEC	0-6 months	25	-	-	-	-	-	-	-	0	2	0	1	-	5	-	-	-	-	-

		7-12 months	57	-	-	-	-	-	-	-	4	4	3	11	-	10	-	-	-	-	-
		13-24 months	33	-	-	-	-	-	-	-	5	1	1	8	-	8	-	-	-	-	-
		25-60 months	11	-	-	-	-	-	-	-	1	0	0	0	-	1	-	-	-	-	-
		15-46 years	126	-	-	-	-	-	-	-	11	7	-	20	2	18	-	-	-	-	-
Lijima et al (2017)	EPEC, EAEC, ETEC, STEC, EHEC, EIEC	-	306	-	-	-	-	-	-	-	138	51	-	50	25	0	-	-	-	-	-
Hassan et al (2014)	*Shigella* spp., *Campylobacter* spp., ETEC	-	4001	-	-	-	-	-	-	240	-	-	-	632	-	-	-	40	-	-	-

Njuguna et al (2016)	*Shigella* spp., *Salmonella* spp., *G. lamblia*, *E. histolytica*	In-patient	284	-	-	-	-	31	6	-	-	-	-	-	-	-	3	67	-	3	169
		Out-patient	114	-	-	-	-	1	1	-	-	-	-	-	-	-	0	1	-	-	-
Terfassa, Jida (2018)	*Salmonella* spp., *Shigella* spp.	-	422	-	-	-	-	-	-	-	-	-	-	-	-	-	30	9	-	-	-
Ferreira et al (2020)	*Cryptosporidium* spp., *E. histolytica*	-	831	-	-	-	28	3	-	-	-	-	-	-	-	-	-	-	-	233	-
Bauhofer et al (2020)	*Cryptosporidium* spp., *G. lamblia*, *E. histolytica*	0-11 months	489 (*E. histolytica*), 478 (*Cryptosporidium* spp.), 477 (*G. lamblia*)	-	-	-	64	9	31	-	-	-	-	-	-	-	-	-	-	-	-
		12-23 months	337 (*E. histolytica*), 331 (*Cryptosporidium* spp.), 330 (*G. lamblia*)	-	-	-	42	6	40	-	-	-	-	-	-	-	-	-	-	-	-

		24-59 months	123 (*E. histolytica*), 121 *Cryptosporidium* spp., *G. lamblia*)	-	-	-	9	4	14	-	-	-	-	-	-	-	-	-	-	-	-
		1-14 years	55	-	-	-	3	1	10	-	-	-	-	-	-	-	-	-	-	-	-
von Huth et al (2019)	*G. lamblia, E. histolytica*	2-7 years (group 1)	471	-	-	-	-	71	150	-	-	-	-	-	-	-	-	-	-	-	-
		2-7 years (group 2)	377	-	-	-	-	58	84	-	-	-	-	-	-	-	-	-	-	-	-
		8-15 years (group 1)	237	-	-	-	-	51	38	-	-	-	-	-	-	-	-	-	-	-	-
		8-15 years (group 2)	189	-	-	-	-	40	32	-	-	-	-	-	-	-	-	-	-	-	-

Garzón et al (2017)	*G. lamblia, Cryptosporidium spp., E. histolytica*	0-3 months	74	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	0	-
		4-6 months	76	-	-	-	1	0	5	-	-	-	-	-	-	-	-	-	-	5	-
		7-9 months	52	-	-	-	3	0	5	-	-	-	-	-	-	-	-	-	-	5	-
		10-12 months	78	-	-	-	3	0	9	-	-	-	-	-	-	-	-	-	-	14	-
		13-16 months	71	-	-	-	2	0	16	-	-	-	-	-	-	-	-	-	-	27	-
		17-18 months	70	-	-	-	1	0	16	-	-	-	-	-	-	-	-	-	-	28	-

		19-24 months	80	-	-	-	3	0	21	-	-	-	-	-	-	-	-	-	-	31	-
Muadica et al (2021)	*Cryptosporidium spp*	-	286	-	-	-	2	-	-	-	-	-	-	-	-	-	-	-	-	126	-
Ramos et al (2014)	*G. lamblia, E. histolytica*	<5 years	6776	-	-	-	-	242	1132	-	-	-	-	-	-	-	-	-	-	574	-
		5-9 years	4601	-	-	-	-	262	810	-	-	-	-	-	-	-	-	-	-	623	-
		10-14 years	2438	-	-	-	-	140	376	-	-	-	-	-	-	-	-	-	-	326	-
		15-19 years	2438	-	-	-	-	163	448	-	-	-	-	-	-	-	-	-	-	289	-

		20-25 years	2592	-	-	-	-	158	372	-	-	-	-	-	-	-	-	-	-	204	-
		25-30 years	3403	-	-	-	-	216	471	-	-	-	-	-	-	-	-	-	-	282	-
		30-35 years	2118	-	-	-	-	142	285	-	-	-	-	-	-	-	-	-	-	186	-
		35-39 years	1836	-	-	-	-	111	230	-	-	-	-	-	-	-	-	-	-	140	-
		40-49 years	2272	-	-	-	-	121	293	-	-	-	-	-	-	-	-	-	-	187	-
		50-59 years	1193	-	-	-	-	67	159	-	-	-	-	-	-	-	-	-	-	89	-

		>59 years	2234	-	-	-	-	111	266	-	-	-	-	-	-	-	-	-	-	286	-
Tellevik et al (2015)	*G. lamblia, E. histolytica*	Out-patient	701	-	-	-	-	0	24	-	-	-	-	-	-	-	-	-	-	140	-
		In-patient	558	-	-	-	-	0	34	-	-	-	-	-	-	-	-	-	-	17	-
Trainor et al (2016)	ETEC	-	1941	-	-	-	-	-	-	-	-	-	-	201	-	-	-	-	-	-	-
Prah et al (2021)	EIEC, EHEC, EPEC, STEC, ETEC, EAEC	-	57	-	-	-	-	-	-	-	6	3	2	25	1	-	-	-	-	-	-
Omolajaiye et al (2020)	EHEC, EIEC, EPEC	0-11 months	15	-	-	-	-	-	-	-	-	8	0	-	0	-	-	-	-	-	-

		1-3 years	31	-	-	-	-	-	-	-	-	6	2	-	0	-	-	-	-	-	-
		3-5 years	19	-	-	-	-	-	-	-	-	3	5	-	8	-	-	-	-	-	-
		5-10 years	5	-	-	-	-	-	-	-	-	1	1	-	2	-	-	-	-	-	-
		>10 years	11	-	-	-	-	-	-	-	-	0	0	-	0	-	-	-	-	-	-
Naguib et al (2018)	*Cryptosporidium spp., G. lamblia*	<3 years	74	-	-	-	2	-	-	-	-	-	-	-	-	-	-	-	-	7	-
		3-4 years	141	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	20	-

		4-5 years	190	-	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-	26	-
		5-6 years	136	-	-	-	2	-	-	-	-	-	-	-	-	-	-	-	-	10	-
		6-7 years	27	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	3	-
		7-8 years	17	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	0	-
Bitilinyu-Bangoh et al (2019)	*Cryptosporidium spp., E. histolytica*	Malawi	175	-	-	-	37	0	-	-	-	-	-	-	-	-	-	-	-	-	-
		Kenya	120	-	-	-	7	0	-	-	-	-	-	-	-	-	-	-	-	-	-

Supplementary Table S4: Pooled proportion estimates of the studies conducted in children <5 years of age, in an in-patient setting.

	Studies with pop. <5 years of age in in-patient facilities					
	Number of studies	Estimated pooled proportion	95% CI	p-value (Wald-type, LR)	Heterogeneity (τ^2)	Variability (I^2)
Rotavirus (with rotavirus vaccine)	4	0.278	[0.185;0.396]	<0.0001, <0.0001	0.098	93.3% [86.1%; 96.8%]
Rotavirus (without rotavirus vaccine)	6	0.234	[0.137;0.37]	<0.0001, <0.0001	0.318	94.4% [90.7%; 96.6%]
Rotavirus without rotavirus vaccine (Infl. cases removed*)	5	0.204	[0.118;0.329]	<0.0001, <0.0001	0.225	91.4% [82.9%; 95.7%]
Norovirus	11	0.076	[0.049;0.116]	<0.0001, <0.0001	0.363	82.8% [70.5%; 89.9%]
Norovirus (excluding G1)	11	0.074	[0.049;0.111]	<0.0001, <0.0001	0.301	79.4% [63.8%; 88.3%]
Astrovirus	7	0.017	[0.004;0.079]	<0.0001, <0.0001	2.509	93.2% [88.5%; 96.0%]
Astrovirus (Infl. Cases removed†)	6	0.012	[0.003;0.04]	Wald: 0.6187; LRT: 0.0001	0.961	0.0% [0.0%; 74.6%]
Campylobacter spp.	6	0.053	[0.013;0.194]	<0.0001, <0.0001	1.609	93.5% [88.4%; 96.3%]
Cryptosporidium	8	0.193	[0.124;0.29]	<0.0001, <0.0001	0.357	87.3% [77.1%; 92.9%]

Cryptosporidium (Infl. cases removed[‡])	7	0.222	[0.159;0.3]	<0.0001, <0.0001	0.165	83.8% [68.2%; 91.8%]
E. histolytica	9	0.018	[0.003;0.108]	<0.0001, <0.0001	4.596	91.6% [86.3%; 94.8%]
EHEC	2	0.147	[0;1]	Wald: 0.0004, LRT: 0.0002	2.679	91.9% [72.0%; 97.7%]
EPEC	8	0.126	[0.065;0.23]	<0.0001, <0.0001	0.605	86.5% [75.5%; 92.6%]
EPEC (excluding aPEC)	9	0.181	[0.06;0.43]	<0.0001, <0.0001	2.351	89.6% [82.5%; 93.8%]
EPEC (Infl. cases removed[§])	8	0.119	[0.058;0.229]	<0.0001, <0.0001	0.849	87.9% [78.5%; 93.2%]
ETEC	6	0.118	[0.075;0.18]	<0.0001, <0.0001	0.158	84.3% [67.5%; 92.4%]
ETEC (excluding LT-ETEC)	6	0.116	[0.058;0.217]	<0.0001, <0.0001	0.428	94.1% [89.8%; 96.6%]
EAEC	4	0.254	[0.159;0.38]	Wald: 0.0006, LRT: 0.0004	0.094	82.7% [55.6%; 93.2%]
EIEC[**]	1	0.8	[0.459;0.95]	-	-	-
STEC[**]	1	0.007	[0.002;0.017]	-	-	-
V. cholerae	4	0.023	[0.006;0.082]	<0.0001, <0.0001	0.458	80.7% [49.5%; 92.7%]
Salmonella spp.	4	0.016	[0.003;0.074]	<0.0001, <0.0001	0.508	72.3% [21.7%; 90.2%]
Shigella spp.	6	0.071	[0.029;0.166]	<0.0001, <0.0001	0.724	90.5% [82.0%; 95.0%]

G. lamblia	9	0.154	[0.084;0.264]	<0.0001, <0.0001	0.753	97.2% [96.0%; 98.0%]
G. lamblia (Infl. cases removed¶)	6	0.123	[0.07;0.206]	<0.0001, <0.0001	0.315	95.5% [92.5%; 97.3%]
Other	29	0.122	[0.082;0.177]	<0.0001, <0.0001	0.234	97.8% [97.4%; 98.2%]
Other (Infl. cases removed‖)	18	0.093	[0.067;0.126]	<0.0001, <0.0001	0.349	88.7% [83.7%; 92.2%]
Unknown	3	0.225	[0.021;0.798]	<0.0001, <0.0001	1.081	98.5% [97.4%; 99.2%]

*Removed as outliers: Nhampossa (2015), 24-59mo
†Removed as outliers: Arowolo (2019)
‡Removed as outliers: Bitilinyu-Bangoh (2019)
§Removed as outliers: Acaio (2019)
¶Removed as outliers: Nhampossa (2015), 24-59mo; Lompo (2021); Tellevik (2015)
‖Removed as outliers: Quédraogo (2016); Japhet (2019); Gasparinho (2016); Nhampossa, group 1(2015); Iturizza-Gómara, group 1 (2019); Iturizza-Gómara, group 2 (2019); Gosselin (2018); Garzón, 13-16mo (2017); Garzón, 17-18mo (2017); Garzón, 19-24mo (2017); Tellevik (2015)
**Point prevalence (Only 1 study available), CI is approximated

Supplementary Table S5: Pooled proportion estimates of the studies conducted in children ≥5 years of age and adults, in an in-patient setting.

	Studies with pop. ≥5 years of age in in-patient facilities					
	Number of studies	Estimated pooled proportion	95% CI	p-value (Wald-type, LR)	Heterogeneity (τ^2)	Variability (I^2)
Rotavirus* (with rotavirus vaccine)	1	0.359	[0.242;0.495]	-	-	-
Rotavirus (without rotavirus vaccine)	0	-	-	-	-	-
Norovirus	0	-	-	-	-	-
Norovirus (excluding G1)	0	-	-	-	-	-
Astrovirus	0	-	-	-	-	-
Campylobacter spp.	0	-	-	-	-	-
Cryptosporidium spp. *	1	0.057	[0.012;0.157]	-	-	-
E. histolytica	11	0.06	[0.056;0.064]	<0.0001, <0.0001	0.003	57.9% [17.8%; 78.5%]
E. histolytica (Infl. cases removed†)	10	0.059	[0.056;0.063]	<0.0001, <0.0001	0.001	24.8% [0.0%; 63.6%]
EHEC*	1	0.143	[0.02;0.581]	-	-	-
EPEC	1	0.143	[0.02;0.581]	-	-	-
EPEC (excluding aEPEC)*	1	0.143	[0.02;0.581]	-	-	-
ETEC	0	-	-	-	-	-
ETEC (excluding LT-ETEC)	0	-	-	-	-	-
EAEC	0	-	-	-	-	-
EIEC*	1	0.286	[0.072;0.673]	-	-	-
STEC	0	-	-	-	-	-
V. cholerae	0	-	-	-	-	-
Salmonella spp.	0	-	-	-	-	-
Shigella spp.	0	-	-	-	-	-

G. lamblia	11	0.129	[0.1;0.164]	<0.0001, <0.0001	0.162	91.4% [86.6%; 94.5%
G. lamblia (Infl. Cases removed‡)	8	0.135	[0.126;0.144]	Wald: 0.0202, LRT: 0.0202	0.004	57.8% [7.6%; 80.8%]
Other	16	0.101	[0.066;0.15]	<0.0001, <0.0001	0.662	97.6% [97.0%; 98.1%]
Other (Infl. cases removed)	13	0.096	[0.082;0.112]	<0.0001, <0.0001	0.065	92.8% [89.5%; 95.1%]
Unknown*	1	0.595	[0.536;0.653]	-	-	-

*Point prevalence (Only 1 study available), CI is approximated
†Removed as outliers: Njaguna (2016), All ages
‡Removed as outliers: Njaguna (2016), All ages; Ramos (2014), 5-9y; Ramos, (2014), 15-19y

Supplementary Table S6: Pooled proportion estimates of the studies conducted in children <5 years of age, in an out-patient and community settings.

	Studies with pop. <5 years of age in out-patient facilities/communities					
	Number of studies	Estimated pooled proportion	95% CI	p-value (Wald-type, LR)	Heterogeneity (τ^2)	Variability (I^2)
Rotavirus (with rotavirus vaccine)	8	0.048	[0.009;0.219]	<0.0001, <0.0001	3.782	93.3% [89.1%; 95.9%]
Rotavirus (Infl. cases removed*)	7	0.035	[0.021;0.058]	<0.0001, <0.0001	3.57	93.3% [88.7%; 96.1%]
Rotavirus (without rotavirus vaccine)	27	0.214	[0.141;0.312]	<0.0001, <0.0001	1.451	97.7% [97.2%; 98.1%]
Rotavirus (Infl. cases removed†)	21	0.179	[0.138;0.228]	<0.0001, <0.0001	0.319	92.6% [90.1%; 94.5%]
Norovirus	28	0.103	[0.065;0.159]	<0.0001, <0.0001	1.412	96.9% [96.2%; 97.4%]
Norovirus (excluding G1)	28	0.103	[0.065;0.159]	<0.0001, <0.0001	1.402	96.8% [96.1%; 97.4%]
Norovirus (Infl. cases removed‡)	18	0.087	[0.061;0.121]	<0.0001, <0.0001	0.339	76.6% [63.3%; 85.1%]
Astrovirus	14	0.03	[0.017;0.051]	<0.0001, <0.0001	0.585	88.4% [82.2%; 92.4%]
Astrovirus (Infl. cases removed§)	12	0.021	[0.015;0.031]	Wald: 0,1088, LRT: 0,1187	0.103	35.2% [0.0%; 67.3%]
Campylobacter spp.	16	0.052	[0.02;0.129]	<0.0001, <0.0001	3.036	98.7% [98.4%; 98.9%]

Campylobacter spp. (Infl. cases removed¶)	11	0.041	[0.024;0.068]	<0.0001, <0.0001	0,044	75.2% [55.2%; 86.3%]
Cryptosporidium	29	0.058	[0.04;0.083]	<0.0001, <0.0001	0.793	89.5% [86.0%; 92.1%]
Cryptosporidium (Infl. cases removed‖)	19	0.047	[0.032;0.067]	Wald: 0.0155, LRT: <0.0001	0.266	45.9% [7.4%; 68.4%]
E. histolytica	17	0.006	[0.001;0.028]	<0.0001, <0.0001	4.804	79.5% [67.9%; 86.9%]
E. histolytica (Infl. cases removed**)	13	0.003	[0.001;0.014]	Wald: 0.6369, LRT: 0.0002	2.249	0.0% [0.0%; 56.6%]
EHEC	5	0.033	[0.011;0.097]	Wald: 0.9872, LRT: 0.5550	0	0.0% [0.0%; 79.2%]
EPEC	14	0.067	[0.047;0.096]	0.0001, <0.0001	0.224	68.1% [44.4%; 81.7%]
EPEC (excluding aEPEC)	15	0.066	[0.035;0.12]	<0.0001, <0.0001	1.127	92.2% [88.8%; 94.6%]
EPEC (Infl. cases removed††)	13	0.059	[0.043;0.081]	Wald: 0.3138; LRT: 0.0729	0.052	13.0% [0.0%; 52.2%]
ETEC	21	0.095	[0.068;0.131]	<0.0001, <0.0001	0.487	89.2% [84.9%; 92.3%];
ETEC (excluding LT-ETEC)	25	0.091	[0.06;0.135]	0	1.005	99.1% [99.0%; 99.2%]
ETEC (Infl. cases removed‡‡)	18	0.087	[0.067;0.112]	<0.0001, <0.0001	0.191	69.1% [49.9%; 81.0%]

EAEC	14	0.155	[0.097;0.24]	<0.0001, <0.0001	0.712	93.3% [90.3%; 95.3%]
EAEC (Infl. cases removed[§§])	10	0.142	[0.096;0.204]	Wald: 0.0086; LRT: 0.0002	0.202	59.3% [18.2%; 79.7%]
EIEC	3	0.021	[0.001;0.429]	Wald: 0.0068; LRT: <0.0001	1.369	80.0% [36.7%; 93.7%]
STEC	8	0.041	[0.007;0.204]	<0.0001, <0.0001	3.951	77.3% [55.1%; 88.6%]
V. cholerae	4	0.002	[0;0.089]	Wald: 0.2573, LRT: 0.0002	2.848	25.7% [0.0%; 71.6%]
Salmonella spp.	11	0.012	[0.005;0.033]	<0.0001, <0.0001	1.586	85.4% [75.6%; 91.3%]
Salmonella spp. (Infl. cases removed[¶¶])	10	0.01	[0.005;0.02]	Wald: 0,0906; LRT: 0,0054	0.477	40.1% [0.0%; 71.4%]
Shigella spp.	15	0.019	[0.01;0.037]	<0.0001, <0.0001	1.158	90.7% [86.4%; 93.7%]
Shigella spp. (Infl. cases removed[‖‖])	12	0.019	[0.01;0.035]	<0.0001, <0.0001	0.696	81.2% [68.2%; 88.9%]
G. lamblia	21	0.13	[0.086;0.193]	<0.0001, <0.0001	0.959	96.1% [95.1%; 97.0%]
G. lamblia (Infl. cases removed[***])	17	0.132	[0.097;0.177]	<0.0001, <0.0001	0.358	80.2% [69.1%; 87.3%]

[*]Removed as outliers: Ashie (2017), 13-24mo

[†]Removed as outliers: Quédraogo (2016); Japhet (2019), 0-5mo; Japhet (2019), 6-11mo; Japhet (2019), 12-23mo; Zimmermann (2019); Mansour (2014)

‡Removed as outliers: Zimmermann, Kenya (2019); Zimmermann, Nigeria (2019); Zimmermann, Mali (2019); Acacio (2019); Nhampossa, 0-11mo (2015); Platts-Mills, 0-11mo (2015); Platts-Mills, 12-24mo (2015); Chuckwu (2020); Imade, 0-6mo (2015); Imade, 7-12mo (2015)
§Removed as outliers: Japhet, 12-23mo(2019); Hungerford (2014)
¶Removed as outliers: Hungerford (2014); Nhampossa, 0-11mo(2015); Platts-Mills, 0-11mo (2015); Chuckwu (2020)
‖Removed as outliers: Zimmermann, Kenya (2019); Gasparinho (2016); Hungerford (2014); Acacio (2019); Bauhofer, 0-11mo(2020); Bauhofer, 12-23mo(2020); Naguib, 4-5y (2018)
**Removed as outliers: Acacio (2019); Nhampossa (2015), 0-11mo; Nhampossa (2015), 12-23mo; Nhampossa (2015), 24-59mo
††Removed as outliers: Lijima (2017)
‡‡Removed as outliers: Gasparinho (2016); Acacio (2019); Nhampossa, 0-11mo (2015); Nhampossa, 12-23mo (2015); Hassan (2014); Prah (2021); Zimmermann, Kenya (2019)
§§Removed as outliers: Gasparinho (2016); Acacio (2019); Nhampossa, 0-11mo (2015); Lijima (2017)
¶¶Removed as outliers: Ashie, 25-60mo (2017)
‖‖Removed as outliers: Acacio, (2019); Nhampossa, 0-11mo (2015); Iturriza-Gómara (2019)
***Removed as outliers: Nhampossa, 12-23mo (2015); Nhampossa, 24-59mo (2015); Ashie, group 2 (2017); Tellevik (2015)

Supplementary Table S7: Pooled proportion estimates of the studies conducted in children ≥5 years of age and adults, in an out-patient and community settings.

	Studies with pop. ≥5 years of age in out-patient facilities/communities					
	Number of subgroups	Estimated pooled proportion	95% CI	p-value (Wald-type, LR)	Heterogeneity (τ^2)	Variability (I^2)
Rotavirus (with rotavirus vaccine)	0	-	-	-	-	-
Rotavirus (without rotavirus vaccine)	0	-	-	-	-	-
Norovirus	0	-	-	-	-	-
Norovirus (excluding G1)	0	-	-	-	-	-
Astrovirus	0	-	-	-	-	-
Campylobacter spp.	0	-	-	-	-	-
Cryptosporidium	6	0.019	[0.007;0.052]	Wald: 0.2302; LRT: 0.035	0.29	27.3% [0.0%; 69.9%]
E. histolytica	7	0.054	[0.011;0.226]	<0.0001, <0.0001	2.798	91.6% [85.2%; 95.2%]
EHEC	0	-	-	-	-	-
EPEC	1	0.028	[0.011;0.056]	-	-	-
EPEC (excluding aPEC)*	1	0.056	[0.023;0.111]	-	-	-
ETEC	1	0.794	[0.052;0.12]	-	-	-
ETEC (excluding LT-ETEC)*	1	0.159	[0.1;0.234]	-	-	-
EAEC*	1	0.087	[0.044;0.151]	-	-	-

EIEC*	1	0.016	[0.002;0.056]	-	-	-
STEC*	1	0.143	[0.087;0.216]	-	-	-
V. cholerae	0	-	-	-	-	-
Salmonella spp.	2	0.011	[0;1]	Wald: 0.9996: LRT: <0.0001	4.591	0%
Shigella spp.	2	0.019	[0;0.523]	Wald: 0.395; LRT: 0.3393	0	0%
G. lamblia	6	0.147	[0.056;0.333]	<0.0001, <0.0001	0.912	88.4% [77.3%; 94.1%]
*Point prevalence (Only 1 study available), CI is approximated						

Supplementary Table S8: Pooled proportion estimates of norovirus, EPEC and ETEC before and after adjusting for potential carriage of pathogens unrelated to diarrhea.

	In-patient setting		Out-patient and community setting	
	<5	≥5	<5	≥5
Norovirus	0.076	-	0.103	-
Norovirus (excluding G1)	0.074	-	0.087	-
ETEC	0.118	-	0.095	0.794
ETEC (excluding LT-ETEC)	0.116	-	0.091	0.159
EPEC	0.126	0.143	0.067	0.028
EPEC (excluding aEPEC)	0.181	0.143	0.066	0.056

Supplementary Table S9: P-value obtained from the Egger's test testing for asymmetry, with number of studies (n). InS = Insufficient number of trials (n<10)

	In-patient studies		Out-patient and community studies	
Pathogen	Population <5 years	Population ≥5 years	Population <5 years	Population ≥5 years
Rotavirus (vaccination)	InS (n = 4)	InS (n = 1)	InS (n = 8)	-
Rotavirus (no vaccination)	InS (n = 6)	-	p-value: 0.4078 (n = 27)	-
Norovirus	p-value: 0.0199 (n = 11)	-	p-value: 0.4269 (n = 28)	-
Astrovirus	InS (n = 7)	-	p-value: 0.2352 (n = 14)	-
Campylobacter spp.	InS (n = 6)	-	p-value: 0.6471 (n = 16)	-
Cryptosporidium spp.	InS (n = 8)	InS (n = 1)	p-value: 0.0032 (n = 29)	InS (n = 6)
Entamoeba histolytica	InS (n = 9)	p-value: 0.2683 (n = 11)	p-value: <0.0001 (n = 17)	InS (n = 7)
Giardia lamblia	InS (n = 9)	InS (n = 1)	p-value: 0.0413 (n = 21)	InS (n = 6)
EHEC	InS (n = 2)	InS (n = 1)	InS (n = 5)	-
EPEC	InS (n = 9)	InS (n = 1)	p-value: 0.4401 (n = 15)	InS (n = 1)
ETEC	InS (n = 6)	-	p-value: 0.0336 (n = 25)	InS (n = 1)
EAEC	InS (n = 4)	-	p-value: 0.0243 (n = 14)	InS (n = 1)
EIEC	InS (n = 1)	InS (n = 1)	InS (n = 3)	InS (n = 1)
STEC	InS (n = 1)	-	InS (n = 8)	InS (n = 1)
Vibrio cholerae	InS (n = 4)	-	InS (n = 4)	-
Salmonella spp.	InS (n = 4)	InS (n = 1)	p-value: 0.2398 (n = 11)	InS (n = 2)
Shigella spp.	InS (n = 6)	InS (n = 1)	p-value: 0.9785 (n = 15)	InS (n = 2)

Supplementary Table S10: Incidence and population estimates from Desta et al.[14] and WHO Global Health Observatory

Incidence (per person-year)						
		Overall	Ethiopia	Mozambique	Nigeria	Tanzania
Annual rate Age-standardized*		0.8 (0.51-1.07)	1.25 (0.22-1.92)	1.85 (0.63-2.8)	0.33 (0.22-0.43)	0.42 (0.22-0.6)
Population estimates (2019) (people-per-year)						
		Northern Africa†	Central Africa‡	Eastern Africa§	Southern Africa¶	Western Africa‖
Children <5		29,097,112	30,190,286	66,871,697	6,788,604	64,211,594
Children ≥ 5 and adults		212,101,195	144,118,141	365,878,161	59,841,290	327,222,492
Total population		241,198,307	174,308,427	432,749,858	66,629,894	391,434,086

*Nigerian census population age proportion was used to standardize the annual incidence rates, given its larger population than the other study countries
†Northern Africa (6): Algeria, Egypt, Libya, Morocco, Sudan, Tunisia
‡Central Africa (9): Angola, Cameroon, Central African Republic, Chad, Congo Republic - Brazzaville, Democratic Republic of Congo, Equatorial Guinea, Gabon, Sao Tome & Principe
§Eastern Africa (18): Burundi, Comoros, Djibouti, Ethiopia, Eritrea, Kenya, Madagascar, Malawi, Mauritius, Mozambique, Rwanda, Seychelles, Somalia, South Sudan, United Republic of Tanzania, Uganda, Zambia, Zimbabwe
¶Southern Africa (5): Botswana, Lesotho, Namibia, South Africa, Eswatini
‖Western Africa (16): Benin, Burkina Faso, Cote D'Ivoire, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Mali, Mauritania, Niger, Nigeria, Senegal, Sierra Leone, Togo

Supplementary Table S11: Incidence and mortality envelope obtained from Global Burden of Disease incidence and mortality envelopes, 2019. Country-specific data were extracted from https://vizhub.healthdata.org/gbd-compare/.

Incidence and mortality envelopes (2019) (people-per-year)					
Incidence envelope	Northern Africa†	Central Africa‡	Eastern Africa§	Southern Africa¶	Western Africa‖
Children <5	54,118,754 (44,642,278-63,755,481)	67,208,529 (54,981,547-78,320,809)	127,161,099 (102,961,981-152,716,741)	5,817,908 (4,618,025-7,208,674)	139,842,581 (113,593,845-166,199,702)
Children ≥ 5 and adults	132,015,596 (112,481,665-153,420,589)	107,681,116 (94,177,091-122,101,397)	260,481,016 (227,412,444-296,049,024)	46,444,006 (41,043,360-52,339,235)	273,022,819 (239,146,168-309,198,041)
Mortality envelope	Northern Africa†	Central Africa‡	Eastern Africa§	Southern Africa¶	Western Africa‖
Children <5	14,302 (6,630-25,444)	71,015 (32,594-123,823)	85,596 (48,761-137,343)	4,588 (3,141-6,515)	194,960 (127,626-286,186)
Children ≥ 5 and adults	2,643 (1,141-5,113)	31,042 (15,756-56,442)	86,711 (42,782-150,149)	11,589 (6,330-21,846)	80,779 (41,962-147,753)
Population estimates (2019) (people-per-year)					
	Northern Africa†	Central Africa‡	Eastern Africa§	Southern Africa¶	Western Africa‖

Children <5	24,959,398	28,263,473	66,268,542	5,986,798	65,167,747
Children ≥ 5 and adults	211,025,201	148,987,192	361,569,179	57,557,168	345,432,446
Total population	235,984,599	177,250,665	427,837,721	63,543,966	410,600,193

[†]Northern Africa (6): Algeria, Egypt, Libya, Morocco, Sudan, Tunisia
[‡]Central Africa (9): Angola, Cameroon, Central African Republic, Chad, Congo Republic - Brazzaville, Democratic Republic of Congo, Equatorial Guinea, Gabon, Sao Tome & Principe
[§]Eastern Africa (18): Burundi, Comoros, Djibouti, Ethiopia, Eritrea, Kenya, Madagascar, Malawi, Mauritius, Mozambique, Rwanda, Seychelles, Somalia, South Sudan, United Republic of Tanzania, Uganda, Zambia, Zimbabwe
[¶]Southern Africa (5): Botswana, Lesotho, Namibia, South Africa, Eswatini
[‖]Western Africa (16): Benin, Burkina Faso, Cote D'Ivoire, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Mali, Mauritania, Niger, Nigeria, Senegal, Sierra Leone, Togo